Charles River Laboratories International, Inc. $CRL Shares Acquired by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 46.5% during the third quarter, Holdings Channel reports. The fund owned 12,962 shares of the medical research company’s stock after acquiring an additional 4,112 shares during the period. Nisa Investment Advisors LLC’s holdings in Charles River Laboratories International were worth $2,028,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CRL. Allspring Global Investments Holdings LLC increased its holdings in Charles River Laboratories International by 29.1% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company’s stock worth $353,750,000 after purchasing an additional 516,521 shares during the period. Ariel Investments LLC grew its position in shares of Charles River Laboratories International by 28.6% during the second quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock worth $214,751,000 after buying an additional 314,572 shares in the last quarter. Invesco Ltd. increased its stake in shares of Charles River Laboratories International by 11.6% during the second quarter. Invesco Ltd. now owns 1,237,143 shares of the medical research company’s stock worth $187,712,000 after buying an additional 128,785 shares during the period. Bank of America Corp DE raised its holdings in Charles River Laboratories International by 29.2% in the second quarter. Bank of America Corp DE now owns 1,026,013 shares of the medical research company’s stock valued at $155,677,000 after acquiring an additional 232,020 shares in the last quarter. Finally, Sei Investments Co. raised its holdings in Charles River Laboratories International by 5.9% in the second quarter. Sei Investments Co. now owns 714,688 shares of the medical research company’s stock valued at $108,440,000 after acquiring an additional 39,959 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on CRL shares. Morgan Stanley set a $185.00 price objective on shares of Charles River Laboratories International in a research report on Monday, December 1st. Weiss Ratings reissued a “sell (d)” rating on shares of Charles River Laboratories International in a report on Wednesday, October 8th. Baird R W raised Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 6th. Evercore ISI upped their price objective on Charles River Laboratories International from $250.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. raised their target price on Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $203.07.

Charles River Laboratories International Trading Up 0.1%

NYSE:CRL opened at $219.01 on Wednesday. The company has a market capitalization of $10.78 billion, a PE ratio of -140.39, a P/E/G ratio of 6.54 and a beta of 1.61. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $228.88. The stock’s 50 day moving average price is $188.76 and its 200 day moving average price is $172.88. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, beating the consensus estimate of $2.32 by $0.11. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.The company’s revenue was down .5% compared to the same quarter last year. During the same period in the prior year, the company earned $2.59 earnings per share. On average, research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.